(Untitled)
Slide 53 of 54
Go to slide:
1: (Untitled)
2: WEIGHT
3: (Untitled)
4: (Untitled)
5: (Untitled)
6: OBESITY MORBIDITY
7: (Untitled)
8: (Untitled)
9: BODY ENERGY USES
10: (Untitled)
11: (Untitled)
12: WAIST-TO-HIP RATIO
13: (Untitled)
14: (Untitled)
15: (Untitled)
16: SEROTONIN
17: SEROTONIN
18: (Untitled)
19: (Untitled)
20: (Untitled)
21: (Untitled)
22: (Untitled)
23: (Untitled)
24: WEIGHT LOSS TREATMENT RESULTS
25: WEIGHT LOSS TREATMENT RESULTS
26: (Untitled)
27: ANTIOBESITY AGENTS
28: PHARMACOTHERAPY
29: (Untitled)
30: (Untitled)
31: (Untitled)
32: (Untitled)
33: (Untitled)
34: (Untitled)
35: (Untitled)
36: (Untitled)
37: (Untitled)
38: PROSPECTS FOR THE FUTURE
39: (Untitled)
40: (Untitled)
41: LEPTIN
42: SIBUTRAMINE
43: ORLISTAT,HYDROLIPSTATIN
44: BROMOCRIPTINE
45: NEUROPEPTIDE Y1 ANTAGONIST
46: NEUROPEPTIDE Y5 ANTAGONIST
47: GALANIN RECEPTOR ANTAGONISTS
48: PANCREATIC LIPASE INHIBITORS
49: HORMONES
50: BETA3 ADRENERGIC RECEPTOR AGONISTS
51: CHOLECYSTOKININ-8 AGONISTS
52: (Untitled)
53: (Untitled)
54: LONG TERM PHARMACOTHERAPY IN OBESITY
